Bio-Techne Corporation
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-81.5% vs price
Base Case (Median)
-69.6% vs price
Bull Case (75th pct.)
-58.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $5.30 | -92.7% | High (40%) |
| PE Comparable | $25.81 | -64.3% | Medium (25%) |
| Growth Trajectory DCF | $56.90 | -21.4% | Medium (20%) |
| Graham Number | $18.78 | -74.1% | Medium (40%) |
| EV/EBITDA | $22.02 | -69.6% | Medium (20%) |
| EV/FCF | $33.75 | -53.4% | Medium (20%) |
| Earnings Power Value | $7.99 | -89.0% | Medium (50%) |
Based on 7 out of 8 methods, TECH appears overvalued at the current price of $72.39. The base case fair value of $22.02 implies 69.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.